LENTIVIRAL-MEDIATED EX-VIVO GENE THERAPY FOR PEDIATRIC PATIENTS WITH SEVERE LEUKOCYTE ADHESION DEFICIENCY-I (LAD-I): INTERIM RESULTS FROM AN ONGOING PHASE 1/2 STUDY

被引：0

作者：

Kohn, Donald ^{[1
]}

Sevilla, Julian ^{[2
,3
]}

Rao, Gayatri ^{[4
]}

Lopez, Maria Chitty ^{[4
]}

Almarza, Elena ^{[4
]}

Terrazas, Dayna ^{[1
]}

Zubicaray, Josune ^{[2
,3
]}

Gonzalez-Vicent, Marta ^{[2
,3
]}

Chetty, Kritika ^{[5
]}

O'Toole, Grainne ^{[5
]}

Xu-Bayford, Jinhua ^{[5
]}

Nicoletti, Eileen ^{[4
]}

Fernandes, Augustine ^{[1
]}

Kuo, Caroline ^{[1
]}

De Oliveira, Satiro ^{[1
]}

Moore, Theodore B. ^{[1
]}

Choi, Grace ^{[4
]}

Zeini, Miriam ^{[4
]}

Mesa-Nunez, Cristina ^{[4
]}

Thrasher, Adrian ^{[5
]}

Bueren, Juan ^{[3
,6
]}

Schwartz, Jonathan ^{[4
,7
]}

Booth, Claire ^{[5
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Hosp Infantil Univ Nino Jesus HIUNJ, Fdn Invest Biomed, Madrid, Spain

[3] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain

[4] Rocket Pharmaceut Inc, Cranbury, NJ USA

[5] UCL Great Ormond St Inst Child Hlth, London, England

[6] Ctr Invest Energet Medioambient & Tecnol CIEMAT, Madrid, Spain

[7] Inst Invest Sanitaria Fdn Jimenez Diaz IIS FJD, Madrid, Spain

来源：

BONE MARROW TRANSPLANTATION | 2023年 / 58卷 / SUPP1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O061

引用

页码：61 / 62

页数：2

共 50 条

[31] Interim Results from a Phase 2/3 Study of the Efficacy and Safety of Ex Vivo Gene Therapy With Lentiviral Vector (Lenti-D) for Childhood Cerebral Adrenoleukodystrophy
Eichler, Florian
Duncan, Christine
Thrasher, Adrian
Shah, Ami
Baruchel, Andre
Paker, Asif
Kohn, Donald
Bratkovic, Drago
Shamir, Esther
Raymond, Gerald
Gaspar, H. Bobby
Amartino, Harnan
Dalle, Jean-Hugues
Larghero, Jerome
Smith, Nicholas
Musolino, Patricia
Gissen, Paul
Orchard, Paul
Sankar, Raman
De Oliveira, Satiro
O'Meara, Tara
Lund, Troy
Miller, Weston
Aubourg, Patrick
Williams, David
NEUROLOGY, 2016, 86
[32] Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of US Phase I Study of Lentiviral-Mediated Ex-VivoFANCA Gene Insertion in Human Stem and Progenitor Cells
Czechowicz, Agnieszka
Roncarolo, Maria Grazia
Beard, Brian C.
Law, Ken
Nicoletti, Eileen
Rio, Paula
Bueren, Juan A.
Schwartz, Jonathan D.
Soni, Sandeep
BLOOD, 2019, 134
[33] Eight induced pluripotent stem cell lines (iPSCs) derived from two patients with Leukocyte adhesion deficiency Type I (LAD I) with mutations in the ITGB2 gene
Fekadu-Siebald, Julia
Fuchs, Nina, V
Zahn, Stella
Rommel, Marcel G. E.
Schenk, Franziska
Huenecke, Sabine
Bremm, Melanie
Kreyenberg, Hermann
Kuci, Zyrafete
Jacobsen, Eva-Maria
Hoenig, Manfred
Schwarz, Klaus
Bader, Peter
Modlich, Ute
Konig, Renate
Bakhtiar, Shahrzad
STEM CELL RESEARCH, 2024, 81
[34] RGX-111 GENE THERAPY FOR THE TREATMENT OF SEVERE MUCOPOLYSACCHARIDOSIS TYPE I (MPS I): INTERIM ANALYSIS OF DATA FROM A PHASE 1/2 STUDY
Wang, Raymond
Ficicioglu, Can
Giugliani, Roberto
Nevoret, Marie-Laure
Fiscella, Michele
Yang, Lin
Cho, Yoonjin
Phillips, Dawn
Falabella, Paulo
MOLECULAR GENETICS AND METABOLISM, 2022, 135 (04) : 305 - 305
[35] Early Results of a Phase I/II Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral βAT87Q-Globin Vector
Soni, Sandeep
Thompson, Alexis A.
Walters, Mark
Leboulch, Philippe
Cavazzana, Marina
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S28 - S29
[36] Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study
Mamcarz, Ewelina
Zhou, Sheng
Lockey, Timothy
Boi, Shannon
Koon-Kiu, Yan
Cross, Shane
Kang, Guolian
Ma, Zhijun
Condori, Jose Marcos
Dowdy, Jolanta
Metais, Jean-Yves
Langfitt, Deanna
Triplett, Brandon
Li, Chen
Zhao, Xiwen
Maron, Gabriela
Suresh, Sneha
Becerra, Juan Carlos Aldave
Church, Joseph
Dokmeci, Elif
Love, James T.
van der Watt, Hedi
da Matta Ain, Ana C.
Krupski, Christa
Yu, Jiyang
Palmer, Lance E.
Janssen, William
De Ravin, Suk See
Weiss, Mitchell J.
Youngblood, Benjamin
Long-Boyle, Janel R.
Meagher, Michael M.
Malech, Harry L.
Puck, Jennifer
Cowan, Morton J.
Gottschalk, Stephen
BLOOD, 2019, 134
[37] Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease
Kanter, Julie
Walters, Mark C.
Hsieh, Matthew M.
Krishnamurti, Lakshmanan
Kwiatkowski, Janet
Kamble, Rammurti T.
von Kalle, Christof
Kuypers, Frans A.
Cavazzana, Marina
Leboulch, Philippe
Joseney-Antoine, Marcelyne
Asmal, Mohammed
Thompson, Alexis A.
Tisdale, John F.
BLOOD, 2016, 128 (22)
[38] Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease
Kanter, Julie
Walters, Mark C.
Hsieh, Matthew
Krishnamurti, Lakshmanan
Kwiatkowski, Janet L.
Kamble, Rammurti
von Kalle, Christof
Joseney-Antoine, Marcelyne
Pierciey, Francis J., Jr.
Shi, Weiliang
Asmal, Mohammed
Thompson, Alexis A.
Tisdale, John F.
BLOOD, 2017, 130
[39] Preliminary Results from the Phase 1/2 GuardOne Trial: A First-in-Human Study of Ex Vivo Lentiviral Gene Therapy (AVR-RD-02) in People with Gaucher Disease Type 1
Jacobsen, L. K.
Trame, M. N.
Golipour, A.
Pfeifer, R.
Khan, A.
Mason, C.
MOLECULAR THERAPY, 2021, 29 (04) : 340 - 340
[40] Interim Results from a Phase I/II Clinical Gene Therapy Study for Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency Using a Safety-Modified Lentiviral Vector and Targeted Reduced Exposure to Busulfan
Mamcarz, Ewelina
Zhou, Sheng
Lockey, Timothy
Abdelsamed, Hossam
Cross, Shane
Ma, Zhijun
Dowdy, Jola
Triplett, Brandon
Weiss, Mitchell J.
Ryu, Byoung Y.
Dokmeci, Elif
Aldave, Juan Carlos
De Ravin, Suk See
Youngblood, Benjamin
Long-Boyle, Janel R.
Meagher, Michael M.
Malech, Harry L.
Puck, Jennifer
Cowan, Morton Jerome
Sorrentino, Brian
BLOOD, 2017, 130

← 1 2 3 4 5 →